The Medical Devices sector report, “Colorectal Cancer Screening Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the Colorectal Cancer Screening Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Colorectal Cancer Screening Tests includes Guaiac Fecal Occult Blood Test (gFOBT) Kits, Immunochemical Fecal Occult Blood Test (iFOBT or FIT) Kits, Fecal DNA Test Kits and Other Colorectal Cancer Screening Tests.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Colorectal Cancer Screening Tests includes Guaiac Fecal Occult Blood Test (gFOBT) Kits, Immunochemical Fecal Occult Blood Test (iFOBT or FIT) Kits, Fecal DNA Test Kits and Other Colorectal Cancer Screening Tests.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Colorectal Cancer Screening Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Colorectal Cancer Screening Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Colorectal Cancer Screening Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Colorectal Cancer Screening Tests - Pipeline Products under Development by Companies
5 Colorectal Cancer Screening Tests Companies and Product Overview
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acuamark Diagnostics Inc
- Anixa Diagnostics Corporation
- Arbele Corp
- Augusta University
- Bar Harbor BioTechnology Inc (Inactive)
- Beacon Biomedical Inc
- Beckman Research Institute Of The City Of Hope
- Beijing Youxun Medical Laboratory Co Ltd
- BGI Genomics Co Ltd
- Biocartis Group NV
- Biome Diagnostics GmbH
- Castle Biosciences Inc
- CellMax Life Inc
- Celtic Medical BV
- CRC Bioscreen
- Creative Biosciences (Guangzhou) Co Ltd
- Curo Biosciences Pvt Ltd
- Diagen
- DiagNodus Ltd
- EHang (Suzhou) Biomedical Co Ltd
- Epigenomics Inc
- Exact Sciences Corp
- Foundation Medicine Inc
- G Medical Health and Wellness
- Geneoscopy LLC
- Genetic Technologies Ltd
- Genetron Health (Beijing) Co Ltd
- Genoptix Inc (Inactive)
- Guardant Health Inc
- Human Metabolome Technologies Inc
- iCellate Medical AB
- Interpace Biosciences Inc
- JL Medi Labs Co Ltd
- Mainz Biomed NV
- mBioSys Pvt Ltd
- Neuome Peptides Pte Ltd
- Oncodiag
- Oncomark Ltd
- Ourotech Ltd
- Prenetics Ltd
- Preora Healthcare Inc
- QuantuMDx Group Ltd
- Rarity Bioscience AB
- Rhythm Biosciences Ltd
- Shanghai Singlera Genomics Technologies Co Ltd
- Singlera Genomics Inc
- The Chinese University of Hong Kong
- University of Oxford
- Vastcon Inc
- VolitionRX Ltd
